WILMINGTON, DE — NRx Pharmaceuticals Inc. (Nasdaq: NRXP) is approaching a November 10 federal regulatory decision on its preservative-free ketamine product after the Food and Drug Administration requested only minor labeling changes, potentially advancing the company’s plans to establish a domestic source of the medication.
The company reported receiving an FDA discipline review letter last week concerning its Abbreviated New Drug Application, or ANDA, for preservative-free ketamine.
According to NRx, the agency classified all requested labeling revisions as minor and instructed the company to submit sample labeling incorporating a proposed proprietary product name that remains under FDA review.
The correspondence comes ahead of the November 10, 2026, target date established under the Generic Drug User Fee Amendments, or GDUFA, framework.
The FDA’s requested changes represent progress in the application review but do not constitute marketing approval. The agency must still complete its regulatory assessment before the product can be commercially distributed.
NRx is also completing final manufacturing process validation runs, a step required to demonstrate that its production processes can consistently meet established specifications.
The manufacturing work is part of the company’s preparations for a potential commercial launch following regulatory clearance.
NRx is positioning the product as a domestically manufactured alternative in a U.S. ketamine market that the company says has experienced repeated supply shortages and relies heavily on overseas production.
“The supply of ketamine in the United States has been primarily from overseas manufacture and American hospitals and doctors have been plagued by repeated shortages of this critically important drug,” said Jonathan Javitt, NRx’s chairman and chief executive officer.
Javitt said the company intends to demonstrate that pharmaceutical manufacturing can be brought back to the United States while offering a preservative-free formulation.
Ketamine is used in medical settings, including as an anesthetic. NRx’s proposed product is distinct from the company’s broader development activities involving neuroplastic therapies for depression, post-traumatic stress disorder and related conditions.
The November 10 goal date marks the FDA’s targeted completion of its application review, with the final regulatory outcome determining whether NRx can proceed toward commercialization.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.